{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:49:14Z","timestamp":1791607754941,"version":"4.3.4"},"reference-count":35,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82572337, 82372059"],"award-info":[{"award-number":["82572337, 82372059"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["82572337, 82372059"],"award-info":[{"award-number":["82572337, 82372059"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Department of Science and Technology of Guangdong Province","doi-asserted-by":"publisher","award":["2025B1111020001"],"award-info":[{"award-number":["2025B1111020001"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"award":["2025B1111020001"],"award-info":[{"award-number":["2025B1111020001"]}],"id":[{"id":"https:\/\/ror.org\/00tjzgn92","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Objectives: To develop and validate a CT radiomics-based machine learning model for the noninvasive prediction of HANS status in advanced HCC and to investigate the prognostic and genomic characteristics associated with HANS status. Materials and Methods: This retrospective study included patients with advanced HCC treated with TACE-based triplet therapy. Patients were followed until death or last follow-up. Tumor tissue underwent whole-exome sequencing for HANS calculation, and arterial-phase CT images were used for radiomic feature extraction. A radiomics model (HANS-Rad), a clinical model (HANS-Clin), and a combined model (HANS-RC) were developed using least absolute shrinkage and selection operator regression. Model performance was evaluated using receiver operating characteristic curve analysis. Calibration and decision curve analyses were performed to assess model reliability and clinical utility. Shapley Additive Explanations (SHAP) were used for model interpretation. Genomic analyses were conducted to explore differences between predicted HANS subgroups. Results: A total of 129 patients were included (median age, 54 years; IQR, 44\u201362 years; 90% men). The HANS-High group demonstrated longer overall survival compared with the HANS-Low group (median, 23.0 vs. 10.0 months; hazard ratio, 0.60; p = 0.026). The combined HANS-RC model achieved the best performance, with an area under the curve (AUC) of 0.964 in the training set and 0.869 (95% CI, 0.716\u20131.000) in the test set, outperforming the radiomics-only and clinical models. The model also showed favorable calibration and net benefit. Genomic analyses revealed that HANS-High tumors exhibited higher tumor mutational burden and enrichment of immune-related and oncogenic pathways, whereas HANS-Low tumors were associated with distinct mutational patterns and pathway alterations. Conclusions: A radiomics-based machine learning model using CT images enables the noninvasive prediction of HANS status in advanced HCC, with strong prognostic relevance and biologic interpretability supported by genomic analyses.<\/jats:p>","DOI":"10.3390\/cancers18193218","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:34:18Z","timestamp":1791279258000},"page":"3218","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interpretable CT-Based Radiomics for Prediction of High-Affinity Neoantigens Associated Immunogenic States in Advanced Hepatocellular Carcinoma Treated with TACE Plus Targeted Therapy and Immunotherapy"],"prefix":"10.3390","volume":"18","author":[{"given":"Chaofan","family":"Bian","sequence":"first","affiliation":[{"name":"Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjin","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5683-5790","authenticated-orcid":false,"given":"Wenzhe","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaping","family":"Li","sequence":"additional","affiliation":[{"name":"Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou 510095, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"779","article-title":"China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int."},{"key":"ref_5","unstructured":"European Association for the Study of the Liver (2025). EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J. Hepatol., 82, 315\u2013374."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102622","DOI":"10.1016\/j.eclinm.2024.102622","article-title":"Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): A target trial emulation study","volume":"72","author":"Jin","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): A multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/HEP.0000000000001229","article-title":"Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages","volume":"82","author":"Yang","year":"2025","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/jamaoncol.2020.3381","article-title":"The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review","volume":"7","author":"Pinter","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41571-023-00816-4","article-title":"Biomarkers for immunotherapy of hepatocellular carcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1053\/j.gastro.2018.11.001","article-title":"Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy","volume":"156","author":"Dhanasekaran","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2020.11.036","article-title":"Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis","volume":"74","author":"Heinrich","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1136\/gutjnl-2020-322196","article-title":"High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells","volume":"70","author":"Liu","year":"2021","journal-title":"Gut"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.acra.2023.11.024","article-title":"CEMRI-Based Quantification of Intratumoral Heterogeneity for Predicting Aggressive Characteristics of Hepatocellular Carcinoma Using Habitat Analysis: Comparison and Combination of Deep Learning","volume":"31","author":"Liu","year":"2024","journal-title":"Acad. Radiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000512028","article-title":"Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma","volume":"10","author":"Chen","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.acra.2024.10.038","article-title":"Multiparametric MRI-based Machine Learning Radiomics for Predicting Treatment Response to Transarterial Chemoembolization Combined with Targeted and Immunotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter Study","volume":"32","author":"Kang","year":"2025","journal-title":"Acad. Radiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e009616","DOI":"10.1136\/jitc-2024-009616","article-title":"Intratumoral and peritumoral radiomics of MRIs predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma","volume":"12","author":"Lin","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2147\/JHC.S513696","article-title":"MRI Radiomics to Predict Early Treatment Response to TACE Combined with Lenvatinib Plus a PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus","volume":"12","author":"Lu","year":"2025","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","article-title":"A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: An imaging biomarker, retrospective multicohort study","volume":"19","author":"Sun","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Liu, D., and Imai, N. (2025). Decision-Making Biomarkers Guiding Therapeutic Strategies in Hepatocellular Carcinoma: From Prediction to Personalized Care. Cancers, 17.","DOI":"10.3390\/cancers17193105"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","article-title":"TREM2(+) macrophages suppress CD8(+) T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma","volume":"79","author":"Tan","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ccell.2025.01.001","article-title":"Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer","volume":"43","author":"Guo","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1038\/ctg.2014.22","article-title":"Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients","volume":"6","author":"Hsu","year":"2015","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cgh.2023.07.029","article-title":"Age-Dependent Female Survival Advantage in Hepatocellular Carcinoma: A Multicenter Cohort Study","volume":"22","author":"Pang","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.chom.2024.03.002","article-title":"A specific enterotype derived from gut microbiome of older individuals enables favorable responses to immune checkpoint blockade therapy","volume":"32","author":"Zhu","year":"2024","journal-title":"Cell Host Microbe"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Guo, Y., Zhang, G., Fu, X., Jiang, S., Li, Y., Li, S., Guo, X., Zhang, X., Zhao, C., and Ding, R. (2026). Hypoxia-related and immune phenotype-related fusion model for non-invasive prognostication of hepatocellular carcinoma treated by TACE: A multicentre study. Gut.","DOI":"10.1136\/gutjnl-2025-337938"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/HEP.0000000000001724","article-title":"Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy","volume":"84","author":"Zhou","year":"2026","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109244","DOI":"10.1016\/j.intimp.2022.109244","article-title":"Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis","volume":"112","author":"Zheng","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3350\/cmh.2024.1088","article-title":"Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway","volume":"31","author":"Aoki","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1245\/s10434-026-19361-2","article-title":"CT-Based Nested Habitats Analysis for Early Recurrence Prediction and Risk Stratification in Hepatocellular Carcinoma: Development and Multicenter Validation Across Four Cohorts","volume":"33","author":"Zhao","year":"2026","journal-title":"Ann. Surg. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"111756","DOI":"10.1016\/j.ejso.2026.111756","article-title":"Preoperative CT-Based Topologically Distinct Intratumoral Heterogeneity Scores for Predicting Intratumoral Tertiary Lymphoid Structures and Outcomes in Hepatocellular Carcinoma: A Multicenter Study","volume":"52","author":"Zhao","year":"2026","journal-title":"Eur. J. Surg. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3218\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:13:12Z","timestamp":1791605592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":35,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193218"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193218","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]}}}